Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH4 | Q9H3N8 | 2/20 | 0.34 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.34 |
| ▸ | NOTUM | Q6P988 | 2/20 | 0.32 |
| ▸ | GABRR1 | P24046 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | AGBL2 | Q5U5Z8 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Oxalic Acid SCHEMBL27357935 | 0.84 | NOTUM (0.37) | NOTUMGABRR1KDM4EHCAR2 | |
| Succinic Acid SCHEMBL19134064 | 0.78 | GABRR1 (0.39) | NOTUMGABRR1KDM4E | |
| 4-Imidazolecarboxylic Acid SCHEMBL20482343 | 0.77 | ASPH (0.36) | HRH4HRH3KDM4EHCAR2 | |
| Ethane SCHEMBL15300165 | 0.76 | — | — | |
| SCHEMBL16694372 | 0.76 | — | — | |
| Iodide SCHEMBL13274496 | 0.76 | — | — | |
| Phosphoric Acid SCHEMBL6231502 | 0.75 | FDPS (0.33) | — | |
| Trifluoroacetic Acid SCHEMBL3641756 | 0.74 | KMT2A (0.39) | HRH4HRH3 | |
| Trifluoroacetic Acid SCHEMBL3826623 | 0.74 | KDM4E (0.46) | KDM4EMAPT | |
| Trifluoroacetic Acid SCHEMBL30271697 | 0.74 | MAPK1 (0.40) | NOTUMKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4658396-A1 | BELT REACTOR MANUFACTURING PROCESS FOR OLIGOMER SYNTHESIS | Arrowhead Pharmaceuticals, Inc. (US) | 2025-12-10 | — | — | EP | claimed |
| WO-2024163644-A1 | BELT REACTOR MANUFACTURING PROCESS FOR OLIGOMER SYNTHESIS | Arrowhead Pharmaceuticals, Inc. (US) | 2024-08-08 | — | — | WO | claimed |
| EP-4658396-A1 | BELT REACTOR MANUFACTURING PROCESS FOR OLIGOMER SYNTHESIS | Arrowhead Pharmaceuticals, Inc. (US) | 2025-12-10 | — | — | EP | disclosed |
| WO-2024163644-A1 | BELT REACTOR MANUFACTURING PROCESS FOR OLIGOMER SYNTHESIS | Arrowhead Pharmaceuticals, Inc. (US) | 2024-08-08 | — | — | WO | disclosed |
| WO-2009021978-A2 | COMPOUNDS CONTAINING CARBABORANE RESIDUES AND THE USE THEREOF IN MEDICINE, ESPECIALLY FOR USE IN TUMOUR THERAPY | UNIVERSITÄT LEIPZIG (DE) | 2009-02-19 | — | — | WO | disclosed |
| US-20060167241-A1 | Method for synthesizing cyclic bisdinucleoside | MITSUI CHEMICALS, INC. (JP) | 2006-07-27 | — | — | US | disclosed |
| EP-1645561-A1 | METHOD OF SYNTHESIZING CYCLIC BISDINUCLEOSIDE | Mitsui Chemicals, Inc. (JP) | 2006-04-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060167241-A1 | Method for synthesizing cyclic bisdinucleoside | NSUN2, POLR2H, POLB | HRH4 2773/4885HRH3 1552/4885NOTUM 3914/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.